Mesoblast (MEOBF) Common Equity (2017 - 2022)

Mesoblast (MEOBF) has disclosed Common Equity for 6 consecutive years, with $497.0 million as the latest value for Q2 2022.

  • Quarterly Common Equity fell 14.51% to $497.0 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $497.0 million through Jun 2022, down 14.51% year-over-year, with the annual reading at $497.0 million for FY2022, 14.51% down from the prior year.
  • Common Equity hit $497.0 million in Q2 2022 for Mesoblast, down from $581.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $581.4 million in Q2 2021 to a low of $481.1 million in Q2 2019.
  • Historically, Common Equity has averaged $531.0 million across 5 years, with a median of $546.0 million in 2018.
  • Biggest five-year swings in Common Equity: grew 14.19% in 2020 and later decreased 14.51% in 2022.
  • Year by year, Common Equity stood at $546.0 million in 2018, then fell by 11.9% to $481.1 million in 2019, then increased by 14.19% to $549.3 million in 2020, then rose by 5.84% to $581.4 million in 2021, then decreased by 14.51% to $497.0 million in 2022.
  • Business Quant data shows Common Equity for MEOBF at $497.0 million in Q2 2022, $581.4 million in Q2 2021, and $549.3 million in Q2 2020.